# ADMA — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-07-02. Informational only, not financial advice.

**Recommendation:** HOLD

**Scores (0–100):** Overall 5.3 · Fundamentals 6.5 · Technicals 3.5 · Growth 6 · Risk 7.5

## Summary

ADMA Biologics presents a classic value-vs-overhang setup: genuine operational strength (43% ROE, 70.5% Q1 gross margin, $55.7M quarterly FCF) trading at 8.6x forward earnings after a -52% YTD drawdown driven by a June 2026 securities lawsuit alleging revenue inflation. With a binary Aug 5 earnings print 34 days out, sequential Q4→Q1 revenue softness ($139M→$114M), and prior EPS/sales surprises of -11.7%/-18.2%, the operational thesis has cracks that the market is punishing appropriately. Hold with tight discipline into the print — cheap on paper, but legal and execution risk dominate.

## Price targets (12-month horizon)

- Bear: $6.50
- Base: $10.00
- Bull: $13.50

## News context

The dominant signal is the June 20, 2026 federal securities lawsuit alleging revenue inflation — this is the reason the stock trades where it does and why forward P/E of 8.6 has not attracted decisive buying. Offsetting that, Raymond James resumed coverage on June 10 (the piece notes 121% implied upside from analyst targets, consistent with the $17.75 consensus target), which suggests at least some institutional analysts view the legal risk as containable. The daily trading-action headlines (Zacks up/down day pieces) are pure noise. The broader market context — crypto selloffs, commodity price stories — is irrelevant to this name. Net: one existential negative catalyst, one modest positive re-engagement signal, and a binary Aug 5 earnings print that will either validate or further impair the operational narrative.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/adma-ai-stock-forecast-50182202ab61135ccbf89bc737846ce3
- AI-generated; model outputs can be wrong. Not financial advice.